CTLA4 and melanoma: Combined ICI therapy with the anti-PD-1 mAb nivolumab, and anti-CTLA-4 mAb ipilimumab in clinical trials for melanoma led to higher rates of hypophysitis than with nivolumab monotherapy [3].